OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
151858

New Century Healthcare Holding Co Ltd

Healthcare Facilities & ServicesVerified

New Century Healthcare Holding Co Ltd has a debt-to-equity ratio of 0.39, indicating a relatively conservative capital structure. However, the company's liquidity position is rated as medium, with a current ratio of 1.29, suggesting limited short-term liquidity cushion. The company's free cash flow is negative at -71.87 million CNY, and operating cash flow is only 17.93 million CNY, indicating cash flow constraints. Profitability metrics are weak, with a return on equity of -26.89% and a return on assets of -15.47%, both significantly below industry norms for healthcare providers. The company reported a net loss of 115.31 million CNY and an operating loss of 71.00 million CNY, highlighting operational inefficiencies. Gross profit of 175.88 million CNY on revenue of 600.099 million CNY suggests margin pressures, with a gross margin of 29.31%. The company operates four segments: Pediatrics, Obstetrics and Gynecology, Hospital Consulting Services, and Others. The Pediatrics and Obstetrics and Gynecology segments are the primary revenue drivers, with the Others segment contributing to ancillary services such as canteens and retail. Revenue concentration is not disclosed, but the domestic market is the sole operational region. Growth trajectory is uncertain, with the company reporting a net loss and negative operating income. Analyst estimates for the last actual revenue were 512.785 million CNY, below the reported 600.099 million CNY, suggesting potential volatility in revenue recognition or reporting. The company's capital expenditure of -9.645 million CNY indicates minimal investment in growth infrastructure. Risk factors include liquidity constraints and a negative net cash position after subtracting total debt. The company's dilution risk is rated as low, with no near-term pressure from share issuance or convertible instruments. However, the negative operating income and net loss raise concerns about long-term sustainability and the ability to service debt. Recent events include the filing of financial results showing a net loss and operating loss, with no significant new developments disclosed in the latest filings or transcripts. The company's financial performance suggests a need for operational restructuring or strategic realignment to address profitability and liquidity challenges.

30-day price · 1518+0.03 (+5.7%)
Low$0.50High$0.70Close$0.56As of22 May, 00:00 UTC
Profile
CompanyNew Century Healthcare Holding Co Ltd
Ticker1518.HK
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
AI analysis

Business. New Century Healthcare Holding Co Ltd operates as an investment holding company primarily engaged in the provision of pediatrics and obstetrics and gynecology specialty services in the domestic market.

Classification. The company is classified under the Healthcare sector, specifically in the Healthcare Facilities & Services industry, with a confidence level of 0.92.

New Century Healthcare Holding Co Ltd has a debt-to-equity ratio of 0.39, indicating a relatively conservative capital structure. However, the company's liquidity position is rated as medium, with a current ratio of 1.29, suggesting limited short-term liquidity cushion. The company's free cash flow is negative at -71.87 million CNY, and operating cash flow is only 17.93 million CNY, indicating cash flow constraints. Profitability metrics are weak, with a return on equity of -26.89% and a return on assets of -15.47%, both significantly below industry norms for healthcare providers. The company reported a net loss of 115.31 million CNY and an operating loss of 71.00 million CNY, highlighting operational inefficiencies. Gross profit of 175.88 million CNY on revenue of 600.099 million CNY suggests margin pressures, with a gross margin of 29.31%. The company operates four segments: Pediatrics, Obstetrics and Gynecology, Hospital Consulting Services, and Others. The Pediatrics and Obstetrics and Gynecology segments are the primary revenue drivers, with the Others segment contributing to ancillary services such as canteens and retail. Revenue concentration is not disclosed, but the domestic market is the sole operational region. Growth trajectory is uncertain, with the company reporting a net loss and negative operating income. Analyst estimates for the last actual revenue were 512.785 million CNY, below the reported 600.099 million CNY, suggesting potential volatility in revenue recognition or reporting. The company's capital expenditure of -9.645 million CNY indicates minimal investment in growth infrastructure. Risk factors include liquidity constraints and a negative net cash position after subtracting total debt. The company's dilution risk is rated as low, with no near-term pressure from share issuance or convertible instruments. However, the negative operating income and net loss raise concerns about long-term sustainability and the ability to service debt. Recent events include the filing of financial results showing a net loss and operating loss, with no significant new developments disclosed in the latest filings or transcripts. The company's financial performance suggests a need for operational restructuring or strategic realignment to address profitability and liquidity challenges.
Key takeaways
  • The company has a weak profitability profile with a negative return on equity and return on assets.
  • Liquidity is constrained, with a current ratio of 1.29 and negative free cash flow.
  • Revenue concentration is not disclosed, but the company operates solely in the domestic market.
  • Capital expenditures are minimal, indicating limited investment in growth.
  • The company's financial performance raises concerns about long-term sustainability and debt servicing.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyCNY
Revenue$600.1M
Gross profit$175.9M
Operating income-$71.0M
Net income-$115.3M
R&D
SG&A
D&A
SBC
Operating cash flow$17.9M
CapEx-$9.6M
Free cash flow-$71.9M
Total assets$745.3M
Total liabilities$316.5M
Total equity$428.8M
Cash & equivalents
Long-term debt$166.2M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0
FY-1
FY-2
FY-3
FY-4
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0
FY-1
FY-2
FY-3
FY-4
PeriodOCFCapExFCFSBC
FY0
FY-1
FY-2
FY-3
FY-4
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$428.8M
Net cash-$166.2M
Current ratio1.3
Debt/Equity0.4
ROA-15.5%
ROE-26.9%
Cash conversion-16.0%
CapEx/Revenue-1.6%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Pharmaceuticals · cohort 25 companies
Metric1518Activity
Op margin-11.8%18.2% medp25 18.2% · p75 24.6%bottom quartile
Net margin-19.2%14.7% medp25 11.7% · p75 28.1%bottom quartile
Gross margin29.3%19.7% medp25 19.7% · p75 39.8%above median
R&D / revenue24.3% medp25 6.6% · p75 24.3%
CapEx / revenue-1.6%4.9% medp25 4.2% · p75 6.3%bottom quartile
Debt / equity39.0%71.3% medp25 19.0% · p75 91.7%below median
Observations
IR observations
Last actual EPS-0.22 CNY
Last actual revenue512,785,000 CNY
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-09 00:04 UTC#2a53e93b
Source: analysis-pipeline (hybrid)Generated: 2026-05-03 11:47 UTCJob: 8e296a7a